Tag Archives: FOAMcc

Practical aspects of renal support in AKI during the COVID-19 Pandemic

Practical aspects of renal support in AKI during the COVID-19 Pandemic

Expert discussion of management of COVID-19 AKI patients and resources, followed by Q&A during last ESICM webinar moderated by Marlies Ostermann, speakers Peter Pickkers and Antoine Schneider. Here the slides!
Peter Pickkers, Dept Intensive Care Medicine, Radboudumc Nijmegen, The Netherlands – Practical aspects of renal support in AKI during the COVID-19 pandemic.


PICKKERS_RRT in COVID AKI final

Dr Antoine G. Schneider MD PhD, Lausanne University Hospital, Lausanne (CHUV), Practical Management of Renal Support in COVID-19 at the Bedside .

SCHNEIDER_Webinar_COVID_CRRT_with comment

Follow dedicated threads on twitter by M. Velia Antonini, @FOAMecmo : first one dedicated to Peter Pickkers’s talk, and the one dedicated to Antoine Schneider’s talk.

Soon webinar replay available here enjoy!

Anti-infective management of COVID-19 Patients

Anti-infective management of COVID-19 patients ESICM webinar moderated by Jan De Waele, speakers Lennie Derde and Matteo Bassetti, focused on antiviral strategies, bacterial co-infections & antibiotics:
Here a twitter thread based on the talk by Lennie Derde, and an infographics based on the talks by Matteo Bassetti by MV Antonini FOAMecmo

Here the slides, replay available at https://bit.ly/35LYB7F

DERDE-20200508_COVID-19_Webinar[LD]

Matteo Bassetti, Clinica Malattie Infettive, Università di Genova – Ospedale Policlinico San Martino-IST Genova, Italy: Antiviral therapy of COVID-19

 

BASSETTI – Terapia COVID-19

Acute Kidney Injury in COVID-19 Patients

Acute Kidney Injury in patients with COVID-19 disease related to SARS-CoV-2 infection: 3 leading experts in AKI and Renal Replacement Therapy shared their experience and in an interesting webinar:
Professor Eric Hoste, Chief of Clinic in the Intensive Care Unit, Ghent University Hospital, Belgium
Marlies Ostermann, Consultant in Critical Care & Nephrology at Guy’s & St. Thomas’ Foundation Trust, London.
moderated by Professor Lui Forni, Consultant in intensive care at Royal Surrey County Hospital NHS Foundation Trust.
sharing their recent experience and observations of cases of AKI in COVID-19 patients
Lui
UK
here the slides, soon replay available on ESICM TV

follow discussion on social media, live posts by David Lyness & Velia Antonini

Eric Hoste: COVID-19 and AKI , Epidemiology & etiology

Marlies Ostermann: Renal replacement therapy

The Surviving Sepsis Campaign Rapid Guidelines on the Management of Critically Ill Adults with COVID-19

The SARS-CoV-2 Coronavirus is the cause of rapidly spreading illness, Coronavirus Disease 2019 COVID-19, which became a pandemic affecting 120,000 individuals in more than 80 countries around the world. Urgent guidance to clinicians caring for the sickest group of these patients is needed! The WHO and the United States CDC have issued preliminary guidance on infection control, screening and diagnosis in the general population, but there is limited guidance on the acute management of critically ills with severe illness due to COVID-19. The COVID-19 surviving sepsis campaign panel, including 36 experts in guideline development, infection control, infectious diseases and microbiology, critical care, emergency medicine, nursing, and public health, from 12 countries, issued several recommendations:
4 best practice statements
9 strong recommendations
34 weak recommendations
support clinicians, allied health professionals, involved policymakers; some guidance to HCWs in low-middle income setting is provided. GRADE approach has been used to assess the quality of evidence. No recommendation feasible for 6 questions. Given the recent emergence of COVID-19, with consideration for limited direct evidence actually existing, indirect evidence on MERS-CoV, SARS-CoV-1, and other coronaviruses, and indirect evidence related to supportive care in ICU from studies on influenza and other respiratory viral infections, ARDS and sepsis has been applied. As relevant new evidence will emerges, it will be used by the panel to update the recommendations as needed, or formulate new recommendations, in what is known as a “living guideline” model.
Full text available, open access link.

As emerging, relevant new evidence as it emerges will be used by the panel to update the recommendations as needed, or formulate new recommendations, in what is known as a “living guideline” model.
Here a series of graphic summaries by Marta Velia Antonini @FOAMecmo

First one, on recommendations on infection Control, diagnosis & testing.

Hemodynamic support: monitoring, fluids & vasoactives.

Non-Invasive Ventilatory support in: SpO2 targets, conventional oxygen therapy, High Flow Nasal Cannula & Non-Invasive Positive Pressure Ventilation.

Invasive mechanical ventilation, recommendations on
MV settings
recruitment maneuver
prone positioning
fluids
neuro-muscolare blocking agents
inhaled vasodilators.

Recommendations on therapy: steroids, antipyretics, antivirals, IVIg, convalescent plasma, rIFNs chloroquine, tocilizumab & more!